Alps Advisors Inc. Has $3.17 Million Holdings in Agios Pharmaceuticals, Inc. (AGIO)
Alps Advisors Inc. raised its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 9.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 47,473 shares of the biopharmaceutical company’s stock after purchasing an additional 3,962 shares during the period. Alps Advisors Inc. owned 0.10% of Agios Pharmaceuticals worth $3,169,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also made changes to their positions in the business. Spark Investment Management LLC increased its position in shares of Agios Pharmaceuticals by 139.9% during the second quarter. Spark Investment Management LLC now owns 84,700 shares of the biopharmaceutical company’s stock valued at $4,357,000 after acquiring an additional 49,400 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Agios Pharmaceuticals by 8.3% during the first quarter. Geode Capital Management LLC now owns 263,899 shares of the biopharmaceutical company’s stock valued at $15,410,000 after acquiring an additional 20,336 shares in the last quarter. Hood River Capital Management LLC boosted its holdings in Agios Pharmaceuticals by 2.3% in the second quarter. Hood River Capital Management LLC now owns 118,844 shares of the biopharmaceutical company’s stock worth $6,115,000 after purchasing an additional 2,626 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Agios Pharmaceuticals by 4.9% in the second quarter. Goldman Sachs Group Inc. now owns 681,093 shares of the biopharmaceutical company’s stock worth $35,042,000 after purchasing an additional 31,969 shares during the last quarter. Finally, Virtu KCG Holdings LLC purchased a new stake in Agios Pharmaceuticals in the second quarter worth approximately $743,000. 93.51% of the stock is owned by institutional investors and hedge funds.
In other Agios Pharmaceuticals news, Director Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock in a transaction on Wednesday, September 13th. The shares were sold at an average price of $65.47, for a total value of $65,470.00. Following the sale, the director now directly owns 86,394 shares in the company, valued at approximately $5,656,215.18. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO David P. Schenkein sold 6,000 shares of Agios Pharmaceuticals stock in a transaction on Friday, September 1st. The shares were sold at an average price of $62.20, for a total transaction of $373,200.00. Following the completion of the sale, the chief executive officer now owns 6,000 shares in the company, valued at $373,200. The disclosure for this sale can be found here. Insiders have sold a total of 178,908 shares of company stock worth $12,147,719 over the last 90 days. Insiders own 10.55% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Alps Advisors Inc. Has $3.17 Million Holdings in Agios Pharmaceuticals, Inc. (AGIO)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2017/11/12/alps-advisors-inc-has-3-17-million-holdings-in-agios-pharmaceuticals-inc-agio.html.
Shares of Agios Pharmaceuticals, Inc. (AGIO) traded down $1.34 during trading on Friday, hitting $62.05. 417,400 shares of the stock traded hands, compared to its average volume of 419,946. Agios Pharmaceuticals, Inc. has a 1-year low of $39.24 and a 1-year high of $72.73.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.78) by $0.19. The firm had revenue of $11.35 million for the quarter, compared to the consensus estimate of $10.85 million. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The company’s revenue was up 26.4% on a year-over-year basis. During the same period last year, the firm earned ($1.63) EPS. equities research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.59 earnings per share for the current fiscal year.
AGIO has been the topic of several research reports. ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Credit Suisse Group raised their target price on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the stock an “outperform” rating in a report on Thursday, November 2nd. BidaskClub cut shares of Agios Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Needham & Company LLC raised their target price on shares of Agios Pharmaceuticals from $54.00 to $72.00 and gave the stock a “buy” rating in a report on Thursday, August 10th. Finally, SunTrust Banks, Inc. restated a “buy” rating and issued a $80.00 target price on shares of Agios Pharmaceuticals in a report on Wednesday, October 4th. Three equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Agios Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $75.70.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).
Receive News & Stock Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.